Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report issued on Friday morning,Benzinga reports. They currently have a $170.00 price objective on the biotechnology company’s stock.

Several other equities research analysts also recently commented on the stock. StockNews.com downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Citigroup lifted their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, Wedbush reiterated an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Trading Down 3.6 %

NASDAQ ASND opened at $122.00 on Friday. The firm’s fifty day simple moving average is $132.40 and its two-hundred day simple moving average is $132.47. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The firm has a market capitalization of $7.40 billion, a P/E ratio of -15.10 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the third quarter worth about $60,000. Price T Rowe Associates Inc. MD raised its position in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares during the period. Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after acquiring an additional 267,881 shares during the period. Acadian Asset Management LLC raised its position in shares of Ascendis Pharma A/S by 1,461.1% in the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the period. Finally, Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.